Felix von Coerper – Startup Investor Profile

Felix von Coerper is the Managing Partner at ALS Investment Fund, specializing in investing in biotech companies developing drugs in the neurodegeneration field, with a focus on ALS. His previous investments include Apic Bio and Bloom Science. With 19 years of experience in venturing, business development & finance, mostly in life sciences, Felix also co-founded MySample BV and served as CEO of the med tech company Elana. ALS Investment Fund collaborates with companies like Amylyx, Emulate, and Orphazyme, among others, supporting neurodegenerative disease research.

Location: Amsterdam, Netherlands

Country: Germany

Investment Regions: EU

Investment Stages: pre-seed, seed

Website: https://www.alsinvestmentfund.com/

AI Reasoning: ALS Investment Fund’s website lists portfolio activity including exits: Amylyx exited in 2023 and Orphazyme exited in 2022. The fund’s portfolio page shows Apic Bio and Bloom Science as investments; Amylyx exit in 2023 indicates investment activity within the past 12 months relative to the reference date, and there is evidence of portfolio updates in 2023. The most recent verifiable investment-related activity is the Amylyx exit in 2023 (investment activity within the last 12 months but more than 6 months ago), corresponding to the “active” range.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.